4-hydroxy-2,2,6,6-tetramethyl-1-hydroxypiperidine

Small moleculeexperimental

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Mar 18, 2011 (NCT01324141)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • 4-hydroxy-2,2,6,6-tetramethyl-1-hydroxypiperidine
  • 4-hydroxy-tempo
  • 4-hydroxy-tempo
  • 4-hydroxy-tempo
  • 4-hydroxy-tempol
  • hotmp
  • n-hydroxy-2,2,6,6-tetramethylpiperidine
  • ot-674
  • tempo-h
  • tempol-h

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01324141Phase 1Mar 18, 2011National Cancer Institute (NCI)
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government1112011
1 organizations
Page 1 / 1